Colon Cancer Treatment - ProlX Pharmaceuticals Corp. Awarded $4.5 Million in Small Business
ProlX Pharmaceuticals Corp. Awarded $4.5 Million in Small Business
Genetic Engineering News - Trx-1, a growth stimulating redox protein, is over-expressed in a wide variety of human tumors, including colon, gastric and pancreatic cancer. PX-12, a small molecule which blocks the growth-promoting activity of Trx-1, has been evaluated in a Phase
AMDL Compiles DR-70(R) Data for U.S. FDA
MSN MoneyCentral - In a study published in the Journal of Immunoassay (1998, vol. 19, pp 63-72) DR-70(R) was shown to detect at least 13 different types of cancer (lung, breast, stomach, liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic, thyroid
Repligen Wins Summary Judgment Against ImClone in Erbitux(R) Case
MSN MoneyCentral - Erbitux(R) was approved by the FDA in February 2004 for certain types of colon cancer. In May 2004, Repligen and MIT filed an action against ImClone for infringement of U.S. Patent No. 4,663,281 based on ImClone’s manufacture and sale of Erbitux(R
Controversial Phillipsburg coach praised at meeting
Allentown Morning Call - James Nicholas, whose pioneering work on sports injuries included four operations on Joe Namath’s knees, has died of colon cancer at age 85. TENNIS Frenchman Paul Henri Mathieu beat Alessio de Mauro of Italy 6-0, 6-3 in the opening round of the
Knowing the answers to these tests can bring about a better grade for
Memphis Commercial Appeal - Colon cancer is the second-leading cause of cancer deaths in America. When and how often: Starting at age 50 for the average-risk patient, or earlier if there is family history or symptoms that may include unexplained rectal bleeding, significant